We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Experimental Live Attenuated Rubella Virus Vaccine Clinical Evaluation of Cendehill Strain

Abel Prinzie, MD; Constant Huygelen, DVM; Jerome Gold, MD; John Farquhar, MD; James McKee, PhD
Am J Dis Child. 1969;118(2):172-177. doi:10.1001/archpedi.1969.02100040174003.
Text Size: A A A
Published online


THE congenital rubella syndrome, originally described by Gregg in 19411 and amply confirmed and documented since then by extensive studies, represents by far the major problem of rubella as a disease. It is now well established that maternal rubella infection during the first trimester of pregnancy is associated with a high incidence of various congenital malformations, stillbirths, and abortions. The rubella epidemic in the United States in 1964, and its toll of many thousand cases of fetal wastage and birth defects, further stressed the urgent need for an effective means of immunization against the disease in order to protect rubella susceptible women before the next epidemic, generally expected in 1970.

Prospects for developing a rubella vaccine originated in 1962 with the report of successful rubella virus isolation in tissue cultures by two independent research groups at Walter Reed2 and at Harvard.3

Since attempts to develop an inactivated


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.